Nanotechnology-driven STING regulation for on-demand therapy
摘要
The combination of cyclic GMP-AMP synthase(cGAS)-stimulator of interferon genes(STING)signaling pathway modulation with nanotechnology offers a promising strategy for the devel-opment of more effective and less toxic therapies.This review summarizes the latest clinical progress of STING agonists and inhibitors,with a particular focus on the role of nanomaterials in regulating the cGAS-STING pathway across a range of diseases.In oncology,STING activation enhances anti-tumor immunity by stimulating immune cells,while nanocarriers improve the stability and targeting pre-cision of STING agonists,facilitating synergistic effects with other immunotherapies.In inflammatory and autoimmune diseases,regulating STING activation helps alleviate the production of excessive pro-inflammatory cytokines,restore immune homeostasis,and prevent tissue damage.Nanomaterials,such as cell-derived membranes,further enhance targeted delivery and biocompatibility,addressing key lim-itations of existing treatment strategies.What distinguishes this review is an in-depth analysis of the cur-rent clinical progress of STING agonists and inhibitors,providing a comprehensive overview of both ongoing clinical trials and preclinical advancements.We also critically evaluate the specific challenges encountered in translating STING nanomaterials into clinical practice.These challenges present signifi-cant barriers to the widespread application of STING-based therapies,underscoring the need for further optimization to realize their full potential.
年,卷(期):
2026, 16(5)
机标分类号:
R392
S852.4
Q786
在线出版日期:
2026年7月1日